Multidrug resistance and prodrug activation for cancer gene therapy of breast cancer

Takuma Fujii; S. Q. Fu; L. H. Yin; T. Nanakorn; Felix Garcia Sanchez; Matt Cooperberg; David Guo; Tao Wang; D. Lin; Giuseppe Pizzorno; Albert Deisseroth

doi:10.1007/BF02966508

Multidrug resistance and prodrug activation for cancer gene therapy of breast cancer

Takuma Fujii, S. Q. Fu, L. H. Yin, T. Nanakorn, Felix Garcia Sanchez, Matt Cooperberg, David Guo, Tao Wang, D. Lin, Giuseppe Pizzorno, Albert Deisseroth

Research output: Contribution to journal › Article › peer-review

Abstract

Current approaches to the treatment of cancer (radiation and chemotherapy) are limited by the toxicity to normal tissues and the sensitivity of tumor cells to these treatments. The use of gene delivery vector systems for the introduction of genetic elements into normal and neoplastic tissues which code for proteins that protect the normal chemotherapy-sensitive tissues and sensitize the tumor cells to radiation and chemotherapy, may contribute to an overall improvement in the outcome of cancer treatment programs. This chapter will review the clinical trials either completed or about to be initiated which are designed to accomplish these goals.

Original language	English
Pages (from-to)	210-212
Number of pages	3
Journal	Breast Cancer
Volume	4
Issue number	4
DOIs	https://doi.org/10.1007/BF02966508
Publication status	Published - 12-1997
Externally published	Yes

All Science Journal Classification (ASJC) codes

Oncology
Radiology Nuclear Medicine and imaging
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/BF02966508

Cite this

@article{2afdde93e97a4f12bd310696188232ce,

title = "Multidrug resistance and prodrug activation for cancer gene therapy of breast cancer",

abstract = "Current approaches to the treatment of cancer (radiation and chemotherapy) are limited by the toxicity to normal tissues and the sensitivity of tumor cells to these treatments. The use of gene delivery vector systems for the introduction of genetic elements into normal and neoplastic tissues which code for proteins that protect the normal chemotherapy-sensitive tissues and sensitize the tumor cells to radiation and chemotherapy, may contribute to an overall improvement in the outcome of cancer treatment programs. This chapter will review the clinical trials either completed or about to be initiated which are designed to accomplish these goals.",

author = "Takuma Fujii and Fu, {S. Q.} and Yin, {L. H.} and T. Nanakorn and Sanchez, {Felix Garcia} and Matt Cooperberg and David Guo and Tao Wang and D. Lin and Giuseppe Pizzorno and Albert Deisseroth",

note = "Funding Information: The authors recognize the support of the Bush Leukemia Research Fund and the Anderson Chair for Cancer Treatment and Research at the UT M. D. Anderson Cancer Center, the Hull Development Fund at the Yale Cancer Center, and the Ensign Professorship of Medicine at the Yale University School of Medicine, and support from NIH P01 CA 49639, NIH P01 CA 55164, and the Ingenex Corporation. Copyright: Copyright 2012 Elsevier B.V., All rights reserved.",

year = "1997",

month = dec,

doi = "10.1007/BF02966508",

language = "English",

volume = "4",

pages = "210--212",

journal = "Breast Cancer",

issn = "1340-6868",

publisher = "Springer Japan",

number = "4",

}

TY - JOUR

T1 - Multidrug resistance and prodrug activation for cancer gene therapy of breast cancer

AU - Fujii, Takuma

AU - Fu, S. Q.

AU - Yin, L. H.

AU - Nanakorn, T.

AU - Sanchez, Felix Garcia

AU - Cooperberg, Matt

AU - Guo, David

AU - Wang, Tao

AU - Lin, D.

AU - Pizzorno, Giuseppe

AU - Deisseroth, Albert

N1 - Funding Information: The authors recognize the support of the Bush Leukemia Research Fund and the Anderson Chair for Cancer Treatment and Research at the UT M. D. Anderson Cancer Center, the Hull Development Fund at the Yale Cancer Center, and the Ensign Professorship of Medicine at the Yale University School of Medicine, and support from NIH P01 CA 49639, NIH P01 CA 55164, and the Ingenex Corporation. Copyright: Copyright 2012 Elsevier B.V., All rights reserved.

PY - 1997/12

Y1 - 1997/12

N2 - Current approaches to the treatment of cancer (radiation and chemotherapy) are limited by the toxicity to normal tissues and the sensitivity of tumor cells to these treatments. The use of gene delivery vector systems for the introduction of genetic elements into normal and neoplastic tissues which code for proteins that protect the normal chemotherapy-sensitive tissues and sensitize the tumor cells to radiation and chemotherapy, may contribute to an overall improvement in the outcome of cancer treatment programs. This chapter will review the clinical trials either completed or about to be initiated which are designed to accomplish these goals.

AB - Current approaches to the treatment of cancer (radiation and chemotherapy) are limited by the toxicity to normal tissues and the sensitivity of tumor cells to these treatments. The use of gene delivery vector systems for the introduction of genetic elements into normal and neoplastic tissues which code for proteins that protect the normal chemotherapy-sensitive tissues and sensitize the tumor cells to radiation and chemotherapy, may contribute to an overall improvement in the outcome of cancer treatment programs. This chapter will review the clinical trials either completed or about to be initiated which are designed to accomplish these goals.

UR - http://www.scopus.com/inward/record.url?scp=84863241106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863241106&partnerID=8YFLogxK

U2 - 10.1007/BF02966508

DO - 10.1007/BF02966508

M3 - Article

AN - SCOPUS:84863241106

SN - 1340-6868

VL - 4

SP - 210

EP - 212

JO - Breast Cancer

JF - Breast Cancer

IS - 4

ER -

Multidrug resistance and prodrug activation for cancer gene therapy of breast cancer

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this